Top

Applied Health Economics and Health Policy

Published in:

01-01-2010 | Correspondence

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis

Authors: Marie-Claude Lefebvre, Elke Hunsche

Published in: Applied Health Economics and Health Policy | Issue 1/2010

Excerpt

Dranitsaris and Mehta[1] reported that, for patients with New York Heart Association functional class (NYHA FC) II/III pulmonary arterial hypertension in Canada, ambrisentan provides the same clinical benefit and is less costly than the other endothelin receptor antagonists (ERAs), bosentan and sitaxentan, and therefore should be considered as the ERA of choice. Their findings were based on a cost-minimization analysis (CMA) and, as they acknowledge, “the primary requirement of a CMA is that all clinical outcomes be equivalent between comparator treatments.” …

Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Appl Health Econ Health Policy 2009; 7(1): 43–59PubMedCrossRef

Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–9PubMedCrossRef

Olschewski H, Galiè N, Kramer M, et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study [abstract]. 102nd International Conference of the American Thoracic Society; 2006 May 19–24; San Diego (CA)

Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119–23PubMedCrossRef

Rubin L, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903PubMedCrossRef

Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patient with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48–54PubMedCrossRef

Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441–7PubMedCrossRef

Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049–56PubMedCrossRef

Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–57PubMedCrossRef

10.

Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555–62PubMedCrossRef

11.

Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(1 Suppl.): S78–84PubMedCrossRef

12.

Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009 Oct; 30 (20): 2493–537

13.

Garin MC, Clark L, Chumney EC, et al. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig 2009; 29(10): 635–46PubMedCrossRef

Title: Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis
Authors: Marie-Claude Lefebvre
Elke Hunsche
Publication date: 01-01-2010
Publisher: Springer International Publishing
Published in: Applied Health Economics and Health Policy / Issue 1/2010
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI: https://doi.org/10.1007/BF03256167

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Healthcare costs in renal transplant recipients using branded versus generic ciclosporin

Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data

Considering the value associated with innovation in health technology appraisal decisions (deliberations)

Is the societal approach wide enough to include relatives?

Inpatient costs of endophthalmitis evaluated for the whole of France

The authors’ reply